Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
about
Catecholaminergic polymorphic ventricular tachycardia: An exciting new eraInherited arrhythmias: The cardiac channelopathiesAntiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC ModelsCatecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry.The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia.A semiquantitative metric for evaluating clinical actionability of incidental or secondary findings from genome-scale sequencingEfficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial.Pharmacotherapy for inherited arrhythmia syndromes: mechanistic basis, clinical trial evidence and practical application.The Safety and Effectiveness of Flecainide in Children in the Current Era.Advances in the pharmacologic treatment of ventricular arrhythmias.Multiple targets for flecainide action: implications for cardiac arrhythmogenesis.Therapeutic Strategies Targeting Inherited Cardiomyopathies.Antiarrhythmic Action of Flecainide in Polymorphic Ventricular Arrhythmias Caused by a Gain-of-Function Mutation in the Nav 1.5 Sodium Channel.
P2860
Q26747056-9D8F1BF6-9EDF-489E-B352-7F27E608F5E7Q26778079-BE553585-C78C-4B6D-9E05-171FE487345FQ28547114-AA5BD40C-D69F-471E-BBB7-FC02238818C0Q33165339-43339FB7-EE8E-4986-BB26-D5849BD9D374Q33167418-27D36512-15AF-4720-98BF-A7D9365A95A9Q36578258-4156DC17-8A84-4742-98ED-344B56BC7866Q38376971-280DA903-7E2D-41F4-906B-1759422F44C9Q38494265-C8AB380D-5BD1-4564-AF7B-75227E912AE9Q38608802-6452DCAA-3FE4-4863-A502-CC9850E649DDQ38619253-22519962-6092-4D15-972A-EECA69C712B6Q39215625-C179499B-C7DC-46FF-8739-36E390E203C6Q39404059-BED820C5-CC1C-4D74-8228-3DCCF940A36AQ39930559-FD36EB3B-9132-445D-A1CA-E5E83504C85A
P2860
Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Flecainide therapy suppresses ...... rphic ventricular tachycardia.
@ast
Flecainide therapy suppresses ...... rphic ventricular tachycardia.
@en
type
label
Flecainide therapy suppresses ...... rphic ventricular tachycardia.
@ast
Flecainide therapy suppresses ...... rphic ventricular tachycardia.
@en
prefLabel
Flecainide therapy suppresses ...... rphic ventricular tachycardia.
@ast
Flecainide therapy suppresses ...... rphic ventricular tachycardia.
@en
P2093
P921
P1433
P1476
Flecainide therapy suppresses ...... rphic ventricular tachycardia.
@en
P2093
Asaad Khoury
Avraham Lorber
Ibrahim Marai
Lior Gepstein
Mahmoud Suleiman
Miry Blich
Monther Boulos
P304
P356
10.1016/J.HRTHM.2013.08.011
P577
2013-08-13T00:00:00Z